Evidence map›Paper›PMID 34019185›Full record

ArticleAnnals of surgical oncology2021

Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Ebbe Billmann Thorgersen, Jørund Asvall, Ida Storhaug Frøysnes, Camilla Schjalm, Stein Gunnar Larsen, Svein Dueland, Yvonne Andersson, Øystein Fodstad, Tom Eirik Mollnes, Kjersti Flatmark

Open access · hybridAbstract read
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Light-enhanced VEGFFrontiers in immunology · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Effect of IntraperitonealTechnology in cancer research & treatment
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ebbe Billmann ThorgersenDepartment of Gastroenterological Surgery, Oslo University Hospital The Radium Hospital, Oslo, Norway. ebbtho@rr-research.no.
Jørund Asvall *Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
Ida Storhaug FrøysnesDepartment of Tumor Biology, Oslo University Hospital The Radium Hospital, Oslo, Norway.
Camilla SchjalmDepartment of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Stein Gunnar LarsenDepartment of Gastroenterological Surgery, Oslo University Hospital The Radium Hospital, Oslo, Norway.
Svein DuelandDepartment of Oncology, Oslo University Hospital The Radium Hospital, Oslo, Norway.
Yvonne AnderssonDepartment of Tumor Biology, Oslo University Hospital The Radium Hospital, Oslo, Norway.
Øystein FodstadDepartment of Tumor Biology, Oslo University Hospital The Radium Hospital, Oslo, Norway.
Tom Eirik MollnesDepartment of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Kjersti FlatmarkDepartment of Gastroenterological Surgery, Oslo University Hospital The Radium Hospital, Oslo, Norway.
Oslo University Hospital · NONorwegian University of Science and Technology · NOUniversity of Oslo · NO

Funding

Norwegian Cancer Society 31384
6 · The paper itself

Abstract

backgroundDespite extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), most patients with resectable peritoneal metastases from colorectal cancer experience disease relapse. MOC31PE immunotoxin is being explored as a novel treatment option for these patients. MOC31PE targets the cancer-associated epithelial cell adhesion molecule, and kills cancer cells by distinct mechanisms, simultaneously causing immune activation by induction of immunogenic cell death (ICD).

methodsSystemic and local cytokine responses were analyzed in serum and intraperitoneal fluid samples collected the first three postoperative days from clinically comparable patients undergoing CRS-HIPEC with (n = 12) or without (n = 26) intraperitoneal instillation of MOC31PE. A broad panel of 27 pro- and antiinflammatory interleukins, chemokines, interferons, and growth factors was analyzed using multiplex technology.

resultsThe time course and magnitude of the systemic and local postoperative cytokine response after CRS-HIPEC were highly compartmentalized, with modest systemic responses contrasting substantial intraperitoneal responses. Administration of MOC31PE resulted in changes that were broader and of higher magnitude compared with CRS-HIPEC alone. Significantly increased levels of innate proinflammatory cytokines, such as interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF) as well as an interesting time response curve for the strong T-cell stimulator interferon (IFN)-γ and its associated chemokine interferon gamma-induced protein/chemokine (C-X-C motif) ligand 10 (IP-10) were detected, all associated with ICD.

conclusionsOur study revealed a predominately local rather than systemic inflammatory response to CRS-HIPEC, which was strongly enhanced by MOC31PE treatment. The MOC31PE-induced intraperitoneal inflammatory reaction could contribute to improve remnant cancer cell killing, but the mechanisms remain to be elucidated in future studies.

Indexed as

Colorectal NeoplasmsHyperthermia, InducedPeritoneal NeoplasmsCombined Modality TherapyCytoreduction Surgical ProceduresHumansHyperthermic Intraperitoneal ChemotherapyImmunoconjugatesImmunoconjugatesMOC31PE immunotoxin

Identifiers

PMID34019185
PMCPMC8349350
OpenAlexW3160650832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.